WEBULL
WebtradeDownload

10x Genomics (TXG) Stock May Be Overvalued On Current Sales

Simply Wall St · 1d ago

10x Genomics has delivered a very large 1 year share price gain, which puts fresh focus on whether the current valuation lines up with its sales base. After such a rapid move, the real question for you is how much revenue power the market is now pricing into the stock.

  • The share price has climbed by a very large amount over the past 12 months. As a result, any misalignment between the business’s sales and the market’s expectations could matter more than usual.
  • A new multi project research collaboration with Fred Hutchinson Cancer Center may support higher sales expectations over time, because it extends 10x Genomics’ single cell and spatial technologies into more cancer settings where adoption could broaden.
  • The analysts covering 10x Genomics have run their own numbers. See what analysts think 10x Genomics's shares could be worth.

The issue now is whether 10x Genomics’ current share price is justified by its sales when set against the Fair Ratio benchmark.

If you want to test the same sales based valuation question you are asking about 10x Genomics across a wider field, take a look at 32 high quality undervalued stocks.

Is 10x Genomics Getting Expensive on Sales?

P/S is a useful lens for 10x Genomics because investors are mainly paying for its revenue base rather than current profits. The stock trades on a P/S multiple of 15.2x, which is far above the Life Sciences industry average of 4.5x and also well ahead of the peer group on roughly 7.0x. The Fair Ratio points to the kind of P/S you might expect for 10x Genomics given factors such as its growth profile, profitability, risk and size, and the current multiple is meaningfully higher than that tailored benchmark. This signals an overvalued reading on this framework.

The fresh collaboration with Fred Hutchinson Cancer Center sets a clear narrative around new use cases for 10x Genomics’ platforms. However, the P/S level already reflects a valuation premium compared with sector norms and closer peers. For anyone weighing the shares today, the key question is how much future revenue strength you believe justifies paying this kind of multiple relative to the company’s Life Sciences peer group. Explore the numbers behind 10x Genomics's P/S valuation.

NasdaqGS:TXG P/S Ratio as at Oct 2026
NasdaqGS:TXG P/S Ratio as at Oct 2026

The 10x Genomics Narrative: What Would Justify Today's Price?

Narratives for 10x Genomics pick up where this valuation puzzle leaves off by spelling out which paths for growth, margins and future earnings would need to play out for the stock to look meaningfully cheap or expensive relative to today’s price. Each one lays out the assumptions behind its fair value so you can watch how those expectations hold up against actual results on Simply Wall St's Community page.

One of the top community narratives on 10x Genomics: 79% overvalued

"The numbers imply that the share price already embeds strong confidence in Atera driven spatial growth, AI linked demand for complex experiments, and progress toward clinical applications..."

Discover why this Narrative puts 10x Genomics at 79% overvalued.

The share price is only one piece of the 10x Genomics puzzle

Price multiples tell you what the market is willing to pay today, yet the real contrast comes from where professional analysts expect this business to be several years from now. Explore where analysts expect 10x Genomics to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.